121 related articles for article (PubMed ID: 11786751)
1. Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma.
Gundlapalli S; Ojha B; Mountz JM
Clin Nucl Med; 2002 Feb; 27(2):140-1. PubMed ID: 11786751
[No Abstract] [Full Text] [Related]
2. [Transitory increase in splenic FDG uptake secondary to the administration of granulocyte colony stimulating factor (G-CSF)].
Ubieto MA; Banzo J
Rev Esp Med Nucl; 2009; 28(1):36. PubMed ID: 19232179
[No Abstract] [Full Text] [Related]
3. Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging.
Chiang SB; Rebenstock A; Guan L; Alavi A; Zhuang H
Clin Nucl Med; 2003 Aug; 28(8):674-6. PubMed ID: 12897658
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.
Sugawara Y; Fisher SJ; Zasadny KR; Kison PV; Baker LH; Wahl RL
J Clin Oncol; 1998 Jan; 16(1):173-80. PubMed ID: 9440740
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's.
Kaste SC; Howard SC; McCarville EB; Krasin MJ; Kogos PG; Hudson MM
Pediatr Radiol; 2005 Feb; 35(2):141-54. PubMed ID: 15654605
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Lymphoma Therapy Using (18)F-FDG PET.
Lowe VJ; Wiseman GA
J Nucl Med; 2002 Aug; 43(8):1028-30. PubMed ID: 12163627
[No Abstract] [Full Text] [Related]
7. Intense FDG uptake in the spleen due to recent granulocyte-macrophage colony-stimulating factor administration: follow-up scan clarifying the situation.
Basu S; Baghel NS
J Cancer Res Ther; 2011; 7(2):228-9. PubMed ID: 21768724
[No Abstract] [Full Text] [Related]
8. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
[TBL] [Abstract][Full Text] [Related]
9. FDG PET for imaging pericardial manifestations of Hodgkin lymphoma.
Buchmann I; Wandt H; Wahl A; Reske SN
Clin Nucl Med; 2003 Sep; 28(9):760-1. PubMed ID: 12973000
[TBL] [Abstract][Full Text] [Related]
10. Interaction of colony-stimulating factors and fluorodeoxyglucose f(18) positron emission tomography.
Mayer D; Bednarczyk EM
Ann Pharmacother; 2002 Nov; 36(11):1796-9. PubMed ID: 12398579
[TBL] [Abstract][Full Text] [Related]
11. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow.
Kazama T; Swanston N; Podoloff DA; Macapinlac HA
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1406-11. PubMed ID: 16133379
[TBL] [Abstract][Full Text] [Related]
12. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S88-95. PubMed ID: 12739340
[No Abstract] [Full Text] [Related]
13. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results.
Sugawara Y; Zasadny KR; Kison PV; Baker LH; Wahl RL
J Nucl Med; 1999 Sep; 40(9):1456-62. PubMed ID: 10492365
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
15. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
16. Intense F-18 FDG accumulation in stomach in a patient with Hodgkin lymphoma: Helicobacter pylori infection as a pitfall in oncologic diagnosis with F-18 FDG PET imaging.
Ak I; Gülbaş Z
Clin Nucl Med; 2005 Jan; 30(1):41. PubMed ID: 15604971
[No Abstract] [Full Text] [Related]
17. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
[TBL] [Abstract][Full Text] [Related]
18. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma.
Kobe C; Dietlein M; Fuchs M
Leuk Lymphoma; 2010 Mar; 51(3):552-3. PubMed ID: 20141443
[No Abstract] [Full Text] [Related]
19. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
20. Can (18)F-FDG PET after first cycle chemotherapy predict the efficacy of therapy in Hodgkin's disease?
Rigacci L; Castagnoli A; Carpaneto A; Carrai V; Vaggelli L; Matteini M
Haematologica; 2002 May; 87(5):ELT24. PubMed ID: 12010684
[No Abstract] [Full Text] [Related]
[Next] [New Search]
